Journal article
ACLS Guidelines 2000: Focus on What’s “New” in the Pulseless Ventricular Tachycardia/Ventricular Fibrillation Algorithm
Journal of pharmacy practice, Vol.15(4), pp.334-343
08/2002
DOI: 10.1177/089719002129041322
Abstract
Despite the use of conventional treatment modalities, the probability of survival for patients experiencing cardiac arrest due to ventricular fibrillation (VF) or pulseless ventricular tachycardia (VT) remains quite poor. Therefore, the management of cardiac arrest remains a challenge. The most recent Advanced Cardiovascular Life Support (ACLS) guidelines have adopted an evidence-based approach toward the treatment of pulseless VT/VF. A number of evidence-based changes have been made in the treatment algorithms for these life-threatening arrhythmias, including the new recommendations for using vasopressin and intravenous amiodarone. This article will provide an overview of the evidence-based approach that was used in the development of the 2000 ACLS guidelines and will summarize the key trials that were used to support the inclusion of vasopressin and intravenous amiodarone in the pulseless VT/VF treatment algorithm. Additionally, dosing and administration issues for these agents will be discussed.
Details
- Title: Subtitle
- ACLS Guidelines 2000: Focus on What’s “New” in the Pulseless Ventricular Tachycardia/Ventricular Fibrillation Algorithm
- Creators
- Cynthia A. Sanoski - University of the Sciences
- Resource Type
- Journal article
- Publication Details
- Journal of pharmacy practice, Vol.15(4), pp.334-343
- DOI
- 10.1177/089719002129041322
- ISSN
- 0897-1900
- eISSN
- 1531-1937
- Number of pages
- 10
- Language
- English
- Date published
- 08/2002
- Academic Unit
- Pharmacy; Pharmacy Practice and Science
- Record Identifier
- 9984721228402771
Metrics
1 Record Views